Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07284290 · ClinicalTrials.gov registry record · Phase 4

Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia

A Phase 4 study of Dementia With Lewy Bodies and Healthy (Controls), sponsored by Virginia Commonwealth University.

Recruiting
Registry status
Phase 4
Development phase
120
Enrollment target
1
Study location

NCT07284290 is a Phase 4 study of Dementia With Lewy Bodies and Healthy (Controls) that is actively recruiting participants, run by Virginia Commonwealth University. The registered enrollment target is 120 participants, below the 466-participant average among 22 other Dementia With Lewy Bodies trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07284290, a Phase 4 study of Dementia With Lewy Bodies and Healthy (Controls), is actively recruiting participants, sponsored by Virginia Commonwealth University.

RECRUITING
Registry status
Phase 4
Development phase
120 participants
Enrollment target
1
Study location

Study Summary

The proposed study aims to address the critical gaps in understanding the mechanisms of CF (Cognitive Fluctuations) by leveraging recently emerged molecular biomarkers, advanced neuroimaging techniques to assess measures of cholinergic degeneration, and synchronous EEG and assessments of attention. One of the overarching innovations of study is combining all of these assessments into one integrated research plan

Conditions Studied

Dementia With Lewy Bodies Healthy (Controls) Parkinson Disease Dementia

Interventions

  • PROCEDURE Syn-One skin biopsy
  • DIAGNOSTIC_TEST Multi modal MRI
  • DIAGNOSTIC_TEST Assessment of dynamic EEG features over 48-hour periods across all study aims
  • DIAGNOSTIC_TEST Plasma biomarkers
  • DRUG Galantamine HBr extended-release 8mg capsules (8mg ER).

Study Locations (1)

Virginia

  • Virginia Commonwealth University - Richmond

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2025-12-08
Est. Completion 2029-11
Phase Phase 4

Sponsor

Virginia Commonwealth University

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07284290

The ClinicalTrials.gov registry entry for NCT07284290 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 466-participant average among 22 other Dementia With Lewy Bodies trials with a reported enrollment target (74% lower). The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Dementia With Lewy Bodies appearing as the primary indexed condition, and to 5 interventions - of which Syn-One skin biopsy is the first listed.

NCT07284290 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.

Frequently Asked Questions

What is clinical trial NCT07284290 about?

NCT07284290 is a clinical study titled "Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia". The proposed study aims to address the critical gaps in understanding the mechanisms of CF (Cognitive Fluctuations) by leveraging recently emerged molecular biomarkers, advanced neuroimaging techniques to assess measures of cholinergic degeneration, and synchronous EEG and assessments of attention. ...

What is the current status of trial NCT07284290?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 2025-12-08. Estimated completion is 2029-11.

What conditions does trial NCT07284290 study?

This clinical trial studies the following conditions: Dementia With Lewy Bodies, Healthy (Controls), Parkinson Disease Dementia.

What interventions are being tested in trial NCT07284290?

The interventions under investigation include: Syn-One skin biopsy (PROCEDURE), Multi modal MRI (DIAGNOSTIC_TEST), Assessment of dynamic EEG features over 48-hour periods across all study aims (DIAGNOSTIC_TEST), Plasma biomarkers (DIAGNOSTIC_TEST), Galantamine HBr extended-release 8mg capsules (8mg ER). (DRUG).

Who is sponsoring clinical trial NCT07284290?

This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07284290 being conducted?

This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Dementia With Lewy Bodies

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Dementia With Lewy Bodies

All registered trials for this condition

Healthy (Controls)

All registered trials for this condition

Virginia

All trials with a study site in Virginia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.